Skip to content

Advertisement

BMC Cancer

What do you think about BMC? Take part in

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors

  • Charles-André Philip2,
  • Ido Laskov1, 2, 4,
  • Marie-Claude Beauchamp1, 2,
  • Maud Marques2,
  • Oreekha Amin2,
  • Joanna Bitharas2,
  • Roy Kessous1, 2,
  • Liron Kogan1, 2,
  • Tahira Baloch2,
  • Walter H. Gotlieb1, 2, 3 and
  • Amber Yasmeen1, 2Email authorView ORCID ID profile
Contributed equally
BMC Cancer201717:638

https://doi.org/10.1186/s12885-017-3639-0

Received: 24 November 2016

Accepted: 1 September 2017

Published: 8 September 2017

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
24 Nov 2016 Submitted Original manuscript
18 Jan 2017 Reviewed Reviewer Report - Kristin Zorn
1 Feb 2017 Reviewed Reviewer Report - Vijay Pandey
9 Mar 2017 Author responded Author comments - Charles-André Philip
Resubmission - Version 2
9 Mar 2017 Submitted Manuscript version 2
27 Jun 2017 Author responded Author comments - Charles-André Philip
Resubmission - Version 3
27 Jun 2017 Submitted Manuscript version 3
25 Jul 2017 Author responded Author comments - Charles-André Philip
Resubmission - Version 4
25 Jul 2017 Submitted Manuscript version 4
7 Aug 2017 Author responded Author comments - Charles-André Philip
Resubmission - Version 5
7 Aug 2017 Submitted Manuscript version 5
28 Aug 2017 Author responded Author comments - Charles-André Philip
Resubmission - Version 6
28 Aug 2017 Submitted Manuscript version 6
Publishing
1 Sep 2017 Editorially accepted
8 Sep 2017 Article published 10.1186/s12885-017-3639-0

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Division of Gynecologic Oncology, Jewish General Hospital, McGill University
(2)
Segal Cancer Center, Lady Davis Institute of Medical Research, McGill University
(3)
Department of Oncology, McGill University
(4)
Department of Obstetrics and Gynecology, Lis Maternity Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv University

Advertisement